source
- Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approachesThe article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monit…
- Evommune pays $30 million to Hinova for rights to develop oral VAV1 molecular glue degrader EVO570 outside ChinaEvommune announced a licensing agreement with Chinese firm Hinova Pharmaceuticals, paying $30 million upfront for access to a preclinical molecular glue program. The agreement gives Evommune the r…